Hubei Biocause Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was CNY 651.78 million compared to net income of CNY 274.05 million a year ago. Basic loss per share from continuing operations was CNY 0.13 compared to basic earnings per share from continuing operations of CNY 0.06 a year ago.